NexImmune, Inc. Common Stock
NEXI
NEXI was delisted on the 11th of July, 2024.
31 hedge funds and large institutions have $2.2M invested in NexImmune, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
52% more capital invested
Capital invested by funds: $1.45M → $2.2M (+$748K)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
7% more funds holding
Funds holding: 29 → 31 (+2)
0.69% less ownership
Funds ownership: 22.85% → 22.15% (-0.69%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
+$389K |
| 2 |
Citigroup
New York
|
+$336K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$122K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$62.4K |
| 5 |
First Manhattan
New York
|
+$52.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$292K |
| 2 |
Goldman Sachs
New York
|
-$225K |
| 3 |
Millennium Management
New York
|
-$113K |
| 4 |
Renaissance Technologies
New York
|
-$105K |
| 5 |
VF
Virtu Financial
New York
|
-$10K |
NEXI Hedge Fund Activity: Q1 2023 in Review
31 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in NexImmune, Inc. Common Stock (NEXI) for Q1 2023, worth a combined $2.2M — up 52% from $1.45M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NEXI positions and 5 closed out — a net gain of 2 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Slate Path Capital, opening a new position worth an estimated $389K. The largest seller was Artal Group, exiting entirely with an estimated $292K sold.
- 31 institutional investors held NexImmune, Inc. Common Stock (NEXI) as of Q1 2023, up from 29 in Q4 2022.
- Funds reported $2.2M of NexImmune, Inc. Common Stock stock for Q1 2023, up 52% quarter-over-quarter.
- 7 funds opened new NexImmune, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of +2 holders.
- The largest NexImmune, Inc. Common Stock buyer in Q1 2023 was Slate Path Capital, an estimated $389K added.
- The largest NexImmune, Inc. Common Stock seller in Q1 2023 was Artal Group, an estimated $292K sold.
Based on aggregated 13F filings for Q1 2023.